Innovation

Solutions: A Symbiotic Relationship

UTHealth researchers are working on a new treatment for oral thrush


By Christine Hall | July 05, 2017

This is a story about a fungus—the cause of some serious infections in hospitalized patients—and a group of microbiologists with McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) who want to develop a new antifungal drug.

Two of the most problematic causes of infections are Enterococcus faecalis, a bacterium, and Candida albicans, a fungus, often found together in the gastrointestinal region. These microbes can also co-habitate in the mouth; some studies have found evidence of both in materials extracted from infected root canals.

The presence of these two microbes in the same parts of the body led Michael Lorenz, Ph.D., a professor of microbiology and molecular genetics at UTHealth, and his colleague, Danielle Garsin, Ph.D., associate professor of microbiology and molecular genetics, to wonder how the organisms might affect one another.

When the researchers put the two organisms together, they noticed something interesting.

“We thought the two together would make infections worse,” Lorenz said. “What ended up happening was unexpected and fascinating: Enterococcus was actually returning Candida to a benign state.”

Doctoral student Carrie Graham deduced that a protein made by the bacterium, EntV, was blocking the fungus’ biofilm development. The interaction was inhibiting the Candida’s virulence, but not harming it. In fact, it was a completely new type of activity for this protein.

Using this newfound knowledge, the researchers wondered if this EntV protein would be effective against a Candida infection, in this case oral thrush—a yeast infection of the mouth and throat that affects millions, particularly babies, seniors and people with weakened immune systems.

In a mouse model, the researchers found that the animals treated with the antimicrobial protein had fewer symptoms—including a reduction in the creamy, white lesions associated with oral thrush—than those who were not treated with the antimicrobial protein. Their results were reported in the April issue of Proceedings of the National Academy of Sciences of the United States of America.

“These findings demonstrate that EntV has potential as an antifungal agent that targets virulence rather than viability,” the researchers wrote in their study.

The next steps are for Garsin’s lab to determine how EntV is produced in Enterococcus, and Lorenz’s lab to determine how EntV makes Candida less infectious. The researchers are also trying to determine how the protein could be used in a clinical setting.

“It’s probably many years away,” Lorenz said, “in part because the protein needs to be modified to make it a suitable therapeutic.”

More testing will determine whether EntV is effective against strains of Candida resistant to traditional antifungals and whether it can be used with them to improve outcomes.

“The long-term goal is to develop a new antifungal drug that takes a different approach to treating oral thrush,” Garsin said.

 




Social Posts

profile_image

Veterans Affairs

@DeptVetAffairs

Employers answer the call at Mayor’s Challenge conference to help prevent suicide https://t.co/4SqzgOFWNj via #VAntagePoint

12 hours ago
profile_image

BCMHouston

@bcmhouston

Dr. Hugo Bellen and his lab are looking into the fruit fly's genes to find the ones that cause neurodevelopment and neurodegenerative disorders. https://t.co/Q9iZDBraWs #research @BCMFomtheLabs

12 hours ago
profile_image

UTHealth

@UTHealth

It was great to see some of the #ManyFacesOfUTHealth working together yesterday at the @UTHealthCIPC mass casualty simulation drill to improve their skill sets and elevate their training! https://t.co/8SD8ipgbUO #collaboration #healthcare

12 hours ago
profile_image

UTHealth

@UTHealth

RT @UTCVSurgery: The @UTHealth @McGovernMed @UTCVSurgery #Vascular team at the @VascularSVS #VAM2018 interactive poster session https://t.c…

12 hours ago
profile_image

UTHealth

@UTHealth

RT @UTHealthCareers: Come Join the #UTHealth Team!!!! We have openings for all positions. Click the link below and join our team!!!! https:…

12 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

VA program using telemedicine to improve care of critically ill patients in regional hospitals appeared to reduce transfers to ICUs at larger facilities without compromising patient survival, researchers said. https://t.co/3shlLvcRbn via @HealthLeaders

13 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

Today’s #VeteranOfTheDay is @USArmy Veteran Joe Lopez. https://t.co/XNJFhMYYlM

14 hours ago
profile_image

Rice University

@RiceUniversity

RT @RiceUNews: Thanks to @MarkBermanFox26 and all the other #Houston media for visiting campus Thursday when we introduced @RiceBaseball's…

14 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

How we’re leading the way in #thyroidcancer treatment: https://t.co/MgHQp9I0Dd #endcancer

14 hours ago
profile_image

Rice University

@RiceUniversity

RT @davidleebron: Here’s the sequel. Gorgeousness from the opposite perspective at the end of the day. https://t.co/TOID4qgnLF

14 hours ago
profile_image

University of Houston

@UHouston

RT @UH_MVP: Come volunteer next Saturday, take some time out of your summer to give back to our Houston community! https://t.co/wIdQtK3LmX

14 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

Today @Ppisters, @svargheseCHRO and other MD Anderson senior leaders set the pace for the President’s Fitness Challenge Row, Ride, Run. Next week, all employees are invited to form teams and try to beat Dr. Pisters’ time. #endcancer https://t.co/kHPILjnwi2

15 hours ago
profile_image

Rice University

@RiceUniversity

RT @CaroMuriel3: “ I don’t know where I’m going from here, but I promise it won’t be boring” David Bowie💃🏻🏃🏽‍♀️ Running on one of the best…

15 hours ago
profile_image

Houston Methodist

@MethodistHosp

@NASARocketMan Thanks for reaching out. Please send a DM so we can get more info & have management follow up ^SF

15 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

ICYMI: Phase II clinical trial offers hope for first new therapeutic option for small cell #lungcancer in more than three decades: https://t.co/kn0V96ak9v #lcsm #endcancer

15 hours ago